优化Belantamab Mafodotin在复发性或耐火性多发性髓瘤中:剂量修改对不良事件和血液学反应的影响在现实世界的回顾性研究中
Lina Zoe Rüsing1, Jakob Schweighofer2, Julia Aschauer2
1Department of Medicine I, Medical University Vienna, 1090 Wien, Austria.
Cancers
|July 29, 2025
概括
在多发性骨髓瘤患者中降低贝兰他马布 (belamaf) 剂量显著降低了严重的角质病变和血小板狭窄. 这种剂量修改改善了耐受性,但没有影响治疗疗效,支持其实际使用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 贝兰他马布 (Belantamab mafodotin) (belamaf) 是一种针对BCMA的抗体药物联合剂,用于耐火性多发性髓瘤.
- 角膜病变是belamaf.f.的一个显著的剂量限制毒性.
- 在某些地区,贝拉玛夫的使用受到限制,因此需要制定策略来控制其毒性.
研究的目的:
- 评估贝兰他马布 (Belantamab) 马福多丁剂量减少对多发性骨髓瘤毒性和疗效的实际影响.
- 评估不良事件的发生率和严重程度,特别是角膜病变,与贝拉玛夫治疗.
- 为了确定剂量修改是否会影响BCMA-naïve患者的治疗结果.
主要方法:
- 对36名在2020年1月至2024年6月期间接受过BCMA先验多发性骨髓瘤患者的复发性/耐药性回顾性分析.
- 接受标准剂量和接受降低剂量 (1.9毫克/千克) 贝兰他马布马福多丁的患者之间的结局的比较.
- 评估不良事件 (特别是角质病变) 和疗效终点 (总体反应率,PFS,OS).
主要成果:
- 总体响应率为64%,响应者的结果明显更好.
- 无进展生存 (PFS) 的中位数为7.3个月,总生存 (OS) 为20.1个月.
- 降低剂量显著降低了3-4级角质炎症 (7%vs. 52%) 和血小板缺血 (33%vs. 67%) 的发生,而不会影响疗效.
结论:
- 减少贝兰他马布 (Belantamab mafodotin) 的剂量是一种可行的策略,可以缓解严重的毒性,特别是角质病变.
- 降低剂量可以改善多发性骨髓瘤患者的耐受性,而不会牺牲治疗疗效.
- 这支持对贝拉玛夫治疗剂量修改的实际实施.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Renal Failure: Dose Adjustments
161
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
161
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.4K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.4K


